ID   LTBP4_HUMAN             Reviewed;        1624 AA.
AC   Q8N2S1; O00508; O75412; O75413;
DT   13-NOV-2007, integrated into UniProtKB/Swiss-Prot.
DT   13-NOV-2007, sequence version 2.
DT   28-JUN-2023, entry version 176.
DE   RecName: Full=Latent-transforming growth factor beta-binding protein 4;
DE            Short=LTBP-4;
DE   Flags: Precursor;
GN   Name=LTBP4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), TISSUE SPECIFICITY, AND VARIANT
RP   MET-1141.
RX   PubMed=9271198; DOI=10.1016/s0014-5793(97)00685-6;
RA   Giltay R., Kostka G., Timpl R.;
RT   "Sequence and expression of a novel member (LTBP-4) of the family of latent
RT   transforming growth factor-beta binding proteins.";
RL   FEBS Lett. 411:164-168(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), SUBCELLULAR LOCATION,
RP   ALTERNATIVE SPLICING, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, INTERACTION
RP   WITH LTBP1 AND TGFB1, AND VARIANTS ILE-194; ALA-787; ALA-820 AND MET-1141.
RC   TISSUE=Heart;
RX   PubMed=9660815; DOI=10.1074/jbc.273.29.18459;
RA   Saharinen J., Taipale J., Monni O., Keski-Oja J.;
RT   "Identification and characterization of a new latent transforming growth
RT   factor-beta-binding protein, LTBP-4.";
RL   J. Biol. Chem. 273:18459-18469(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Embryo;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [5]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16157329; DOI=10.1016/j.yexcr.2005.08.008;
RA   Koli K., Hyytieainen M., Ryynanen M.J., Keski-Oja J.;
RT   "Sequential deposition of latent TGF-beta binding proteins (LTBPs) during
RT   formation of the extracellular matrix in human lung fibroblasts.";
RL   Exp. Cell Res. 310:370-382(2005).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [7]
RP   INTERACTION WITH EFEMP2.
RX   PubMed=27339457; DOI=10.1016/j.matbio.2016.06.003;
RA   Sasaki T., Hanisch F.G., Deutzmann R., Sakai L.Y., Sakuma T., Miyamoto T.,
RA   Yamamoto T., Hannappel E., Chu M.L., Lanig H., von der Mark K.;
RT   "Functional consequence of fibulin-4 missense mutations associated with
RT   vascular and skeletal abnormalities and cutis laxa.";
RL   Matrix Biol. 56:132-149(2016).
RN   [8]
RP   VARIANT URDS GLY-311.
RX   PubMed=19836010; DOI=10.1016/j.ajhg.2009.09.013;
RA   Urban Z., Hucthagowder V., Schuermann N., Todorovic V., Zilberberg L.,
RA   Choi J., Sens C., Brown C.W., Clark R.D., Holland K.E., Marble M.,
RA   Sakai L.Y., Dabovic B., Rifkin D.B., Davis E.C.;
RT   "Mutations in LTBP4 cause a syndrome of impaired pulmonary,
RT   gastrointestinal, genitourinary, musculoskeletal, and dermal development.";
RL   Am. J. Hum. Genet. 85:593-605(2009).
RN   [9]
RP   VARIANTS ILE-194; ALA-787; ALA-820 AND MET-1141, AND INVOLVEMENT IN DMD.
RX   PubMed=23440719; DOI=10.1002/ana.23819;
RG   United Dystrophinopathy Project;
RA   Flanigan K.M., Ceco E., Lamar K.M., Kaminoh Y., Dunn D.M., Mendell J.R.,
RA   King W.M., Pestronk A., Florence J.M., Mathews K.D., Finkel R.S.,
RA   Swoboda K.J., Gappmaier E., Howard M.T., Day J.W., McDonald C.,
RA   McNally E.M., Weiss R.B.;
RT   "LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular
RT   dystrophy.";
RL   Ann. Neurol. 73:481-488(2013).
RN   [10]
RP   VARIANT MET-1141, AND INVOLVEMENT IN DMD.
RX   PubMed=25641372; DOI=10.1002/ana.24370;
RG   Cooperative International Neuromuscular Research Group Investigators;
RA   Bello L., Kesari A., Gordish-Dressman H., Cnaan A., Morgenroth L.P.,
RA   Punetha J., Duong T., Henricson E.K., Pegoraro E., McDonald C.M.,
RA   Hoffman E.P.;
RT   "Genetic modifiers of ambulation in the Cooperative International
RT   Neuromuscular Research Group Duchenne Natural History Study.";
RL   Ann. Neurol. 77:684-696(2015).
CC   -!- FUNCTION: Key regulator of transforming growth factor beta (TGFB1,
CC       TGFB2 and TGFB3) that controls TGF-beta activation by maintaining it in
CC       a latent state during storage in extracellular space. Associates
CC       specifically via disulfide bonds with the Latency-associated peptide
CC       (LAP), which is the regulatory chain of TGF-beta, and regulates
CC       integrin-dependent activation of TGF-beta.
CC       {ECO:0000250|UniProtKB:Q14766}.
CC   -!- SUBUNIT: Forms part of the large latent transforming growth factor beta
CC       precursor complex; removal is essential for activation of complex
CC       (PubMed:9660815). Interacts with LTBP1 and TGFB1 (PubMed:9660815).
CC       Interacts with EFEMP2; this interaction promotes fibrillar deposition
CC       of EFEMP2 (PubMed:27339457). {ECO:0000269|PubMed:27339457,
CC       ECO:0000269|PubMed:9660815}.
CC   -!- INTERACTION:
CC       Q8N2S1; O15265: ATXN7; NbExp=2; IntAct=EBI-947718, EBI-708350;
CC       Q8N2S1; O00555: CACNA1A; NbExp=2; IntAct=EBI-947718, EBI-766279;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix {ECO:0000269|PubMed:16157329, ECO:0000269|PubMed:9660815}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=LTBP-4L;
CC         IsoId=Q8N2S1-1; Sequence=Displayed;
CC       Name=2; Synonyms=LTBP-4S;
CC         IsoId=Q8N2S1-2; Sequence=VSP_029364, VSP_029365;
CC       Name=3;
CC         IsoId=Q8N2S1-3; Sequence=VSP_029363;
CC       Name=4;
CC         IsoId=Q8N2S1-4; Sequence=VSP_029362, VSP_029366, VSP_029367;
CC   -!- TISSUE SPECIFICITY: Highly expressed in heart, skeletal muscle,
CC       pancreas, uterus, and small intestine. Weakly expressed in placenta and
CC       lung. {ECO:0000269|PubMed:9271198, ECO:0000269|PubMed:9660815}.
CC   -!- DEVELOPMENTAL STAGE: Very low expression in fetal brain, liver, heart,
CC       spleen and thymus. {ECO:0000269|PubMed:9660815}.
CC   -!- PTM: Contains hydroxylated asparagine residues.
CC       {ECO:0000250|UniProtKB:Q14766}.
CC   -!- DISEASE: Urban-Rifkin-Davis syndrome (URDS) [MIM:613177]: A syndrome
CC       characterized by disrupted pulmonary, gastrointestinal, urinary,
CC       musculoskeletal, craniofacial and dermal development. Clinical features
CC       include cutis laxa, mild cardiovascular lesions, respiratory distress
CC       with cystic and atelectatic changes in the lungs, and diverticulosis,
CC       tortuosity and stenosis at various levels of the intestinal tract.
CC       Craniofacial features include microretrognathia, flat midface, receding
CC       forehead and wide fontanelles. {ECO:0000269|PubMed:19836010}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Duchenne muscular dystrophy (DMD) [MIM:310200]: Most common
CC       form of muscular dystrophy; a sex-linked recessive disorder. It
CC       typically presents in boys aged 3 to 7 year as proximal muscle weakness
CC       causing waddling gait, toe-walking, lordosis, frequent falls, and
CC       difficulty in standing up and climbing up stairs. The pelvic girdle is
CC       affected first, then the shoulder girdle. Progression is steady and
CC       most patients are confined to a wheelchair by age of 10 or 12. Flexion
CC       contractures and scoliosis ultimately occur. About 50% of patients have
CC       a lower IQ than their genetic expectations would suggest. There is no
CC       treatment. {ECO:0000269|PubMed:23440719, ECO:0000269|PubMed:25641372}.
CC       Note=The gene represented in this entry may act as a disease modifier.
CC       DMD patients homozygous for the IAAM haplotype consisting of Ile-194,
CC       Ala-787, Ala-820 and Met-1141 remain ambulatory significantly longer
CC       than those heterozygous or homozygous for the VTTT haplotype consisting
CC       of Val-194, Thr-787, Thr-820 and Thr-1141. This may be due to increased
CC       binding to TGFB1, resulting in TGFB1 sequestration in the extracellular
CC       matrix and reduced TGFB1 signaling which has been linked to improved
CC       muscle function and regeneration. {ECO:0000269|PubMed:23440719}.
CC   -!- SIMILARITY: Belongs to the LTBP family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y13622; CAA73944.1; -; mRNA.
DR   EMBL; AF051344; AAC39879.2; -; mRNA.
DR   EMBL; AF051345; AAC39880.2; -; mRNA.
DR   EMBL; AK074499; BAC11024.1; -; mRNA.
DR   EMBL; AC010412; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS74368.1; -. [Q8N2S1-3]
DR   CCDS; CCDS74369.1; -. [Q8N2S1-1]
DR   CCDS; CCDS74370.1; -. [Q8N2S1-2]
DR   RefSeq; NP_001036009.1; NM_001042544.1. [Q8N2S1-1]
DR   RefSeq; NP_001036010.1; NM_001042545.1. [Q8N2S1-2]
DR   RefSeq; NP_003564.2; NM_003573.2.
DR   AlphaFoldDB; Q8N2S1; -.
DR   BioGRID; 114009; 85.
DR   IntAct; Q8N2S1; 56.
DR   MINT; Q8N2S1; -.
DR   STRING; 9606.ENSP00000311905; -.
DR   CarbonylDB; Q8N2S1; -.
DR   GlyCosmos; Q8N2S1; 17 sites, 3 glycans.
DR   GlyGen; Q8N2S1; 34 sites, 5 O-linked glycans (29 sites).
DR   iPTMnet; Q8N2S1; -.
DR   PhosphoSitePlus; Q8N2S1; -.
DR   BioMuta; LTBP4; -.
DR   DMDM; 160410003; -.
DR   EPD; Q8N2S1; -.
DR   jPOST; Q8N2S1; -.
DR   MassIVE; Q8N2S1; -.
DR   MaxQB; Q8N2S1; -.
DR   PaxDb; Q8N2S1; -.
DR   PeptideAtlas; Q8N2S1; -.
DR   ProteomicsDB; 71731; -. [Q8N2S1-1]
DR   ProteomicsDB; 71732; -. [Q8N2S1-2]
DR   ProteomicsDB; 71733; -. [Q8N2S1-3]
DR   ProteomicsDB; 71734; -. [Q8N2S1-4]
DR   Antibodypedia; 4199; 92 antibodies from 17 providers.
DR   DNASU; 8425; -.
DR   Ensembl; ENST00000308370.11; ENSP00000311905.8; ENSG00000090006.18. [Q8N2S1-1]
DR   Ensembl; ENST00000396819.8; ENSP00000380031.5; ENSG00000090006.18. [Q8N2S1-2]
DR   GeneID; 8425; -.
DR   KEGG; hsa:8425; -.
DR   MANE-Select; ENST00000396819.8; ENSP00000380031.5; NM_001042545.2; NP_001036010.1. [Q8N2S1-2]
DR   UCSC; uc032hxp.2; human. [Q8N2S1-1]
DR   AGR; HGNC:6717; -.
DR   CTD; 8425; -.
DR   DisGeNET; 8425; -.
DR   GeneCards; LTBP4; -.
DR   GeneReviews; LTBP4; -.
DR   HGNC; HGNC:6717; LTBP4.
DR   HPA; ENSG00000090006; Low tissue specificity.
DR   MalaCards; LTBP4; -.
DR   MIM; 310200; phenotype.
DR   MIM; 604710; gene.
DR   MIM; 613177; phenotype.
DR   neXtProt; NX_Q8N2S1; -.
DR   OpenTargets; ENSG00000090006; -.
DR   Orphanet; 221145; Cutis laxa with severe pulmonary, gastrointestinal and urinary anomalies.
DR   Orphanet; 98896; Duchenne muscular dystrophy.
DR   PharmGKB; PA30480; -.
DR   VEuPathDB; HostDB:ENSG00000090006; -.
DR   eggNOG; KOG1217; Eukaryota.
DR   GeneTree; ENSGT00940000158234; -.
DR   InParanoid; Q8N2S1; -.
DR   OMA; NHAGICE; -.
DR   OrthoDB; 354414at2759; -.
DR   PhylomeDB; Q8N2S1; -.
DR   TreeFam; TF317514; -.
DR   PathwayCommons; Q8N2S1; -.
DR   Reactome; R-HSA-2129379; Molecules associated with elastic fibres.
DR   Reactome; R-HSA-2173789; TGF-beta receptor signaling activates SMADs.
DR   SignaLink; Q8N2S1; -.
DR   BioGRID-ORCS; 8425; 7 hits in 323 CRISPR screens.
DR   ChiTaRS; LTBP4; human.
DR   GenomeRNAi; 8425; -.
DR   Pharos; Q8N2S1; Tbio.
DR   PRO; PR:Q8N2S1; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q8N2S1; protein.
DR   Bgee; ENSG00000090006; Expressed in tibial nerve and 175 other tissues.
DR   ExpressionAtlas; Q8N2S1; baseline and differential.
DR   Genevisible; Q8N2S1; HS.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; HDA:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; HDA:BHF-UCL.
DR   GO; GO:0001527; C:microfibril; ISS:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; TAS:ProtInc.
DR   GO; GO:0005539; F:glycosaminoglycan binding; NAS:UniProtKB.
DR   GO; GO:0005178; F:integrin binding; NAS:UniProtKB.
DR   GO; GO:0050431; F:transforming growth factor beta binding; IDA:UniProtKB.
DR   GO; GO:0005024; F:transforming growth factor beta receptor activity; NAS:UniProtKB.
DR   GO; GO:0048251; P:elastic fiber assembly; ISS:UniProtKB.
DR   GO; GO:0046879; P:hormone secretion; IEA:Ensembl.
DR   GO; GO:0006457; P:protein folding; TAS:UniProtKB.
DR   GO; GO:0001558; P:regulation of cell growth; TAS:UniProtKB.
DR   GO; GO:0017015; P:regulation of transforming growth factor beta receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IEA:Ensembl.
DR   CDD; cd00054; EGF_CA; 13.
DR   Gene3D; 2.10.25.10; Laminin; 20.
DR   Gene3D; 3.90.290.10; TGF-beta binding (TB) domain; 4.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR017878; TB_dom.
DR   InterPro; IPR036773; TB_dom_sf.
DR   PANTHER; PTHR24034; EGF-LIKE DOMAIN-CONTAINING PROTEIN; 1.
DR   PANTHER; PTHR24034:SF168; UROMODULIN LIKE 1; 1.
DR   Pfam; PF07645; EGF_CA; 17.
DR   Pfam; PF12661; hEGF; 1.
DR   Pfam; PF00683; TB; 3.
DR   SMART; SM00181; EGF; 20.
DR   SMART; SM00179; EGF_CA; 19.
DR   SUPFAM; SSF57196; EGF/Laminin; 4.
DR   SUPFAM; SSF57184; Growth factor receptor domain; 6.
DR   SUPFAM; SSF57581; TB module/8-cys domain; 4.
DR   PROSITE; PS00010; ASX_HYDROXYL; 14.
DR   PROSITE; PS00022; EGF_1; 2.
DR   PROSITE; PS01186; EGF_2; 12.
DR   PROSITE; PS50026; EGF_3; 15.
DR   PROSITE; PS01187; EGF_CA; 17.
DR   PROSITE; PS51364; TB; 4.
PE   1: Evidence at protein level;
KW   Alternative splicing; Disease variant; Disulfide bond; EGF-like domain;
KW   Extracellular matrix; Glycoprotein; Growth factor binding;
KW   Reference proteome; Repeat; Secreted; Signal.
FT   SIGNAL          1..27
FT                   /evidence="ECO:0000255"
FT   CHAIN           28..1624
FT                   /note="Latent-transforming growth factor beta-binding
FT                   protein 4"
FT                   /id="PRO_0000310964"
FT   DOMAIN          149..181
FT                   /note="EGF-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          287..339
FT                   /note="TB 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00697"
FT   DOMAIN          357..397
FT                   /note="EGF-like 2; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          407..459
FT                   /note="TB 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00697"
FT   DOMAIN          545..586
FT                   /note="EGF-like 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          587..628
FT                   /note="EGF-like 4; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          629..670
FT                   /note="EGF-like 5; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          671..708
FT                   /note="EGF-like 6; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          710..751
FT                   /note="EGF-like 7; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          752..793
FT                   /note="EGF-like 8; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          834..877
FT                   /note="EGF-like 9; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          878..919
FT                   /note="EGF-like 10; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          920..960
FT                   /note="EGF-like 11; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1049..1090
FT                   /note="EGF-like 12; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1181..1235
FT                   /note="TB 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00697"
FT   DOMAIN          1253..1295
FT                   /note="EGF-like 13; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1296..1337
FT                   /note="EGF-like 14; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1349..1402
FT                   /note="TB 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00697"
FT   DOMAIN          1533..1573
FT                   /note="EGF-like 15"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1574..1618
FT                   /note="EGF-like 16"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   REGION          125..146
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          474..546
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1130..1179
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1446..1524
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        482..497
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1149..1170
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1446..1462
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   CARBOHYD        352
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        425
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1055
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1200
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1339
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        153..163
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        157..169
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        171..180
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        289..311
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00697"
FT   DISULFID        298..324
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00697"
FT   DISULFID        312..327
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00697"
FT   DISULFID        361..372
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        367..381
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        383..396
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        409..431
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00697"
FT   DISULFID        418..444
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00697"
FT   DISULFID        432..447
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00697"
FT   DISULFID        433..459
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00697"
FT   DISULFID        549..561
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        556..570
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        572..585
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        591..603
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        598..612
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        614..627
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        633..645
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        640..654
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        656..669
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        675..687
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        682..696
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        698..707
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        714..726
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        721..735
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        737..750
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        756..768
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        763..777
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        779..792
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        838..851
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        845..860
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        862..876
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        882..894
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        888..903
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        905..918
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        924..935
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        930..944
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        946..959
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1053..1065
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1059..1074
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1076..1089
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1183..1206
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00697"
FT   DISULFID        1193..1218
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00697"
FT   DISULFID        1193
FT                   /note="Interchain (with C-33 in TGFB1); in linked form"
FT                   /evidence="ECO:0000250|UniProtKB:Q14766"
FT   DISULFID        1207..1223
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00697"
FT   DISULFID        1208..1235
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00697"
FT   DISULFID        1218
FT                   /note="Interchain (with C-33 in TGFB1); in linked form"
FT                   /evidence="ECO:0000250|UniProtKB:Q14766"
FT   DISULFID        1257..1270
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1265..1279
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1281..1294
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1300..1312
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1307..1321
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1323..1336
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1351..1375
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00697"
FT   DISULFID        1361..1387
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00697"
FT   DISULFID        1376..1390
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00697"
FT   DISULFID        1377..1402
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00697"
FT   DISULFID        1537..1548
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1543..1557
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1559..1572
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1578..1593
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1588..1602
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        1604..1617
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   VAR_SEQ         1..902
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_029362"
FT   VAR_SEQ         1..68
FT                   /note="MPRPGTSGRRPLLLVLLLPLFAAATSAASPSPSPSQVVEVPGVPSRPASVAV
FT                   CRCCPGQTSRRSRCIR -> MGDVKALLFVVAARARRLGGAAASESLAVSE (in
FT                   isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:9271198"
FT                   /id="VSP_029363"
FT   VAR_SEQ         1..67
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9660815"
FT                   /id="VSP_029364"
FT   VAR_SEQ         68..151
FT                   /note="RAFCRVRSCQPKKCAGPQRCLNPVPAVPSPSPSVRKRQVSLNWQPLTLQEAR
FT                   ALLKRRRPRGPGGRGLLRRRPPQRAPAGKAPV -> MAGGVRLLWVSLLVLLAQLGPQP
FT                   GLGRLGERLRVRFTPVVCGLRCVHGPTGSRCTPTCAPRNATSVDSGAPGGAAPGGPGFR
FT                   AF (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9660815"
FT                   /id="VSP_029365"
FT   VAR_SEQ         903..919
FT                   /note="CTCAPGYRPGPRGASCL -> MLGGAGGGPGLRTPCPA (in isoform
FT                   4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_029366"
FT   VAR_SEQ         1007..1092
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_029367"
FT   VARIANT         194
FT                   /note="V -> I (in dbSNP:rs2303729)"
FT                   /evidence="ECO:0000269|PubMed:23440719,
FT                   ECO:0000269|PubMed:9660815"
FT                   /id="VAR_037119"
FT   VARIANT         311
FT                   /note="C -> G (in URDS; dbSNP:rs267607229)"
FT                   /evidence="ECO:0000269|PubMed:19836010"
FT                   /id="VAR_064153"
FT   VARIANT         635
FT                   /note="R -> G (in dbSNP:rs33937741)"
FT                   /id="VAR_037120"
FT   VARIANT         679
FT                   /note="P -> A (in dbSNP:rs34299942)"
FT                   /id="VAR_037121"
FT   VARIANT         787
FT                   /note="T -> A (in dbSNP:rs1131620)"
FT                   /evidence="ECO:0000269|PubMed:23440719,
FT                   ECO:0000269|PubMed:9660815"
FT                   /id="VAR_037122"
FT   VARIANT         820
FT                   /note="T -> A (in dbSNP:rs1051303)"
FT                   /evidence="ECO:0000269|PubMed:23440719,
FT                   ECO:0000269|PubMed:9660815"
FT                   /id="VAR_037123"
FT   VARIANT         1141
FT                   /note="T -> M (in dbSNP:rs10880)"
FT                   /evidence="ECO:0000269|PubMed:23440719,
FT                   ECO:0000269|PubMed:9271198, ECO:0000269|PubMed:9660815"
FT                   /id="VAR_037124"
FT   CONFLICT        170
FT                   /note="L -> F (in Ref. 1; CAA73944)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        346
FT                   /note="T -> A (in Ref. 3; BAC11024)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        526
FT                   /note="L -> F (in Ref. 2; AAC39879/AAC39880)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        686
FT                   /note="A -> G (in Ref. 1; CAA73944)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        974
FT                   /note="G -> R (in Ref. 3; BAC11024)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1139
FT                   /note="A -> V (in Ref. 1; CAA73944)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1142
FT                   /note="F -> S (in Ref. 1; CAA73944)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1151
FT                   /note="A -> V (in Ref. 1; CAA73944)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1165
FT                   /note="P -> S (in Ref. 1; CAA73944)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1169..1170
FT                   /note="ST -> RK (in Ref. 1; CAA73944)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1173
FT                   /note="Q -> K (in Ref. 1; CAA73944)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1180
FT                   /note="R -> C (in Ref. 1; CAA73944)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1402
FT                   /note="C -> R (in Ref. 3; BAC11024)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1512
FT                   /note="P -> S (in Ref. 3; BAC11024)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1546
FT                   /note="G -> D (in Ref. 1; CAA73944)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1624 AA;  173435 MW;  75682D1F6E40657A CRC64;
     MPRPGTSGRR PLLLVLLLPL FAAATSAASP SPSPSQVVEV PGVPSRPASV AVCRCCPGQT
     SRRSRCIRAF CRVRSCQPKK CAGPQRCLNP VPAVPSPSPS VRKRQVSLNW QPLTLQEARA
     LLKRRRPRGP GGRGLLRRRP PQRAPAGKAP VLCPLICHNG GVCVKPDRCL CPPDFAGKFC
     QLHSSGARPP APAVPGLTRS VYTMPLANHR DDEHGVASMV SVHVEHPQEA SVVVHQVERV
     SGPWEEADAE AVARAEAAAR AEAAAPYTVL AQSAPREDGY SDASGFGYCF RELRGGECAS
     PLPGLRTQEV CCRGAGLAWG VHDCQLCSER LGNSERVSAP DGPCPTGFER VNGSCEDVDE
     CATGGRCQHG ECANTRGGYT CVCPDGFLLD SSRSSCISQH VISEAKGPCF RVLRDGGCSL
     PILRNITKQI CCCSRVGKAW GRGCQLCPPF GSEGFREICP AGPGYHYSAS DLRYNTRPLG
     QEPPRVSLSQ PRTLPATSRP SAGFLPTHRL EPRPEPRPDP RPGPELPLPS IPAWTGPEIP
     ESGPSSGMCQ RNPQVCGPGR CISRPSGYTC ACDSGFRLSP QGTRCIDVDE CRRVPPPCAP
     GRCENSPGSF RCVCGPGFRA GPRAAECLDV DECHRVPPPC DLGRCENTPG SFLCVCPAGY
     QAAPHGASCQ DVDECTQSPG LCGRGACKNL PGSFRCVCPA GFRGSACEED VDECAQEPPP
     CGPGRCDNTA GSFHCACPAG FRSRGPGAPC QDVDECARSP PPCTYGRCEN TEGSFQCVCP
     MGFQPNTAGS ECEDVDECEN HLACPGQECV NSPGSFQCRT CPSGHHLHRG RCTDVDECSS
     GAPPCGPHGH CTNTEGSFRC SCAPGYRAPS GRPGPCADVN ECLEGDFCFP HGECLNTDGS
     FACTCAPGYR PGPRGASCLD VDECSEEDLC QSGICTNTDG SFECICPPGH RAGPDLASCL
     DVDECRERGP ALCGSQRCEN SPGSYRCVRD CDPGYHAGPE GTCDDVDECQ EYGPEICGAQ
     RCENTPGSYR CTPACDPGYQ PTPGGGCQDV DECRNRSFCG AHAVCQNLPG SFQCLCDQGY
     EGARDGRHCV DVNECETLQG VCGAALCENV EGSFLCVCPN SPEEFDPMTG RCVPPRTSAG
     TFPGSQPQAP ASPVLPARPP PPPLPRRPST PRQGPVGSGR RECYFDTAAP DACDNILARN
     VTWQECCCTV GEGWGSGCRI QQCPGTETAE YQSLCPHGRG YLAPSGDLSL RRDVDECQLF
     RDQVCKSGVC VNTAPGYSCY CSNGYYYHTQ RLECIDNDEC ADEEPACEGG RCVNTVGSYH
     CTCEPPLVLD GSQRRCVSNE SQSLDDNLGV CWQEVGADLV CSHPRLDRQA TYTECCCLYG
     EAWGMDCALC PAQDSDDFEA LCNVLRPPAY SPPRPGGFGL PYEYGPDLGP PYQGLPYGPE
     LYPPPALPYD PYPPPPGPFA RREAPYGAPR FDMPDFEDDG GPYGESEAPA PPGPGTRWPY
     RSRDTRRSFP EPEEPPEGGS YAGSLAEPYE ELEAEECGIL DGCTNGRCVR VPEGFTCRCF
     DGYRLDMTRM ACVDINECDE AEAASPLCVN ARCLNTDGSF RCICRPGFAP THQPHHCAPA
     RPRA
//
